{"Clinical Trial ID": "NCT00290745", "Intervention": ["INTERVENTION 1:", "- Tamoxifene or letrozole", "Tamoxifen or letrozole work in the treatment of women with in situ channel carcinoma", "- Letrozole", "- Tamoxifen citrate", "\u2022 Conventional surgery", "Neoadjuvant treatment"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Diagnosis of canalal carcinoma in situ (CDIS) on the nucleus biopsy", "No evidence of contralateral breast disease or palpable masses during breast examination", "No presence or suspicion of invasive cancer, including contralateral invasive cancer, on central biopsy and MRI", "No ipsilateral axillary adenopathy documented", "Consider a mastectomy or mastectomy", "- Positive oestrogen receptor (ER) tumour by immunohistochemistry", "CHARACTERISTICS OF PATIENTS:", "Women", "Premenopausal or postmenopausal", "The postmenopausal is defined by one of the following characteristics:", "No spontaneous period for >= 1 year", "- Bilateral oophorectomy", "Radiation and amenorrhoea for >= 3 months", "(e.g. hormone replacement therapy or contraceptive pill) for >= 1 month", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "There would be no comorbidity to the use of tamoxifen, including any of the following:", "58/1 Previous history of thrombotic events", "History of hypercoagulable state", "History of Endometrial Hyperplasia", "Abnormal vaginal haemorrhage", "No history of allergies/reactions related to contrasting dyes", "No history of prostheses or implants containing metals", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics"], "Results": ["Performance measures:", "Median change in 6-month tumour volume from baseline use of mammography", "The variation in the size of the ductal carcinoma in situ (CDIS) in participants in hormone therapy, determined by mammography, is determined by (1) the largest tumour diameter, as seen on mammography (2) the extent of the disease on mammography (3) the quantification of the mammographically detected change of the inclusion at 6 months and used to generate the change in the tumour volume of the mammographic extent of the disease from inclusion.", "Time frame: baseline and 6 months", "Results 1:", "Title of arm/group: Tamoxifene or L\u00e9trozole", "Description of the arm/group: tamoxifen or letrozole work in the treatment of women with in situ channel carcinoma", "- Letrozole", "- Tamoxifen citrate", "\u2022 Conventional surgery", "Neoadjuvant treatment", "Total number of participants analysed: 54", "Median (interquartile range)", "Unit of measurement: change in tumour volume (mm) -5.0 (-10.4 to 0.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/0"]}